Peter Riedell MD

Peter Riedell, MD, provides comprehensive care for adults with Hodgkin and non-Hodgkin lymphomas. In particular, he has a special interest in the use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed and aggressive lymphomas.

As an active clinical researcher, Dr. Riedell serves as principal investigator on several ongoing clinical trials evaluating the role of stem cell transplantation and cellular therapy in the treatment of patients with a range of lymphoma subtypes. His research interests include better characterizing the safety and efficacy of cellular therapy, and in particular, collaborating with translational scientists to better understand the mechanisms of CAR T-cell failure and resistance. He is also actively involved in developing innovative treatment options incorporating targeted agents, along with cellular and immunotherapy approaches.